Clinical Resource: CDK4/6 Inhibitor Therapy in HR+, HER2– Breast Cancer

The information provided in this resource is for educational purposes only. Although the information is derived from medical literature, its correctness, comprehensiveness, or currency cannot be guaranteed. Healthcare professionals should apply clinical judgement and follow institutional guidelines and Health Canada Product Monograph guidance as it relates to individual patient care. The authors and supporting medical writing agency cannot assume any legal liability for any damage incurred directly or indirectly from the information.

CANO/ACIO and CAPhO have made every effort to ensure that information included within this programme is accurate at the time of endorsement. The information included cannot substitute for the advice or direction of a healthcare professional, and the associations make no guarantees, nor can they assume any legal liability for the accuracy, completeness, or usefulness of such information or for any damage incurred directly or indirectly from the information. Reference to any specific product does not imply its endorsement, recommendation, or preference by the Canadian Association of Nurses in Oncology or the Canadian Association of Pharmacy in Oncology.